A single-center observational study of more than 1,000 oncological examinations has demonstrated that PET/ MRI facilitates cancer staging as well as PET/CT and improves lesion detectability in select cancers, potentially helping to promote fast, efficient local and whole-body staging in one step. The study, published in The Journal of Nuclear Medicine, also shows that PET/MRI significantly reduces overall radiation exposure when compared to PET/CT—of particular benefit to pediatric and adolescent patients.
While PET/CT is known as the diagnostic cornerstone in various oncologic imaging guidelines due to its sensitivity and high-resolution morphologic imaging, PET/MRI has higher soft-tissue contrast and lower radiation exposure. However, clinical data for PET/MRI are scarce due to the lack of clinical studies with relevant sample sizes.
In the observational study, a total of 1,003 whole-body PET/MRI examinations on 918 patients from a single center were compared with whole-body PET/CT examinations of the same patients. The oncological indications included lung cancer, gastrointestinal cancer or neuroendocrine cancer, gynecologic or breast cancer, prostate cancer, lymphoma, melanoma, head and neck cancer, cancer of unknown primary and malignant bone disease.
Board-certified nuclear medicine physicians and radiologists evaluated the examinations to identify additional findings on PET/MRI that were missing on PET/CT and probable diagnoses; additional but indeterminate findings on PET/MRI requiring additional examinations or follow-up; classification of indeterminate findings on PET/CT by PET/MRI; and missed findings on PET/MRI in comparison to PET/CT. Effective dose of both modalities was also investigated.
Additional information on PET/MRI was reported for 26.3% of examinations, compared with PET/CT. Of these, additional malignant findings were detected in 5.3%, leading to a change in TNM staging in 2.9% due to PET/MRI. Definite lesion classification of indeterminate PET/CT findings was possible in 11.1% with PET/MRI. In 2.9%, lesions detected on PET/CT were not visible on PET/MRI. Malignant lesions were missed in 1.2% on PET/MRI, leading to a change in TNM staging in 0.5%. The estimated mean effective dose for whole-body PET/CT amounted to 17.6 ± 8.7 mSv, in comparison to 3.6 ± 1.4 mSv for PET/MRI, resulting in a potential dose reduction of 79.6%.
“Due to the higher soft tissue contrast, PET/MRI improves lesion detection and reduces the need for additional examinations in comparison to PET/CT,” says Benedikt Schaarschmidt, MD, professor and radiologist at the University Hospital Essen in Germany. “Especially in younger patients who need repeated diagnostic procedures, our data advocate the use of PET/MRI due to the markedly reduced radiation exposure of PET/MRI when compared to PET/CT.”
He continues, “Hybrid imaging examinations are now part of complex diagnostic algorithms in multiple cancer types. Based on our data, PET/MRI could be an important adjunct to PET/CT by providing diagnostic advantages and improving diagnostic algorithms in numerous cancers at the same time. Furthermore, the markedly reduced radiation exposure of PET/MRI could lead to a more frequent use of this examination in oncological patients, most notably for treatment monitoring.”
Featured image: Indeterminate lesion on PET/CT classified by PET/MRI for 53-y-old man with lung cancer. Contrast-enhanced CT (A), PET (B), and fused 18F-FDG PET/CT (C) images are displayed in comparison with contrast-enhanced T1-weighted MRI (D), PET, and fused 18F-FDG PET/MRI (F) images. In CT (A), hyperdense, subcentimeter liver lesion (arrows) in segment VII is suggestive of transient hepatic attenuation difference or small hemangioma. As malignancy cannot be excluded, it needs further investigation. On PET/MRI, lesion is clearly classified as metastasis because of contrast enhancement and tracer uptake due to later acquisition time point. Follow-up CT confirmed diagnosis after 78 d.